ArticleProceedings of the National Academy of Sciences of the United States of America2023
Engineered calprotectin-sensing probiotics for IBD surveillance in humans.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Adhesion-Enhanced Engineered Probiotic for Prolonged Intestinal Retention and Calprotectin-Responsive IBD Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineering commensal microbes for host health.Cell host & microbe · 2026Review
- Metabolic host-microbe crosstalk in stabilization of epithelial HIF.Microbiome · 2026Article
- Engineering smart bacteria for the next generation.Cell reports. Medicine · 2026Review
- Biosensor-Based Detection of Calprotectin and Lactoferrin as Neutrophil-Derived Markers of Inflammatory Bowel Diseases: From Molecular Pathophysiology to Point-of-Care Platforms.International journal of molecular sciences · 2026Review
- Theranostic Probiotic Engineered Living Materials That Dynamically Respond to Inflammation Markers.Advanced healthcare materials · 2026Article
- Escherichia coli gene expression is influenced more by gut environmental changes from inflammation and microbiota modulation than by colitis severity.Scientific reports · 2025Article
- Probiotic acoustic biosensors for noninvasive imaging of gut inflammation.Nature communications · 2025Article
- Synthetic Biology-Based Engineering Living Therapeutics for Antimicrobial Application.Exploration (Beijing, China) · 2025Article
- Microbial Biosensor for Sensing and Treatment of Intestinal Inflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools.International journal of molecular sciences · 2025Review
- Potential applications of engineered bacteria in disease diagnosis and treatment.Microbiome research reports · 2025Review
- One small step for stool, one giant leap for IBD surveillance.Tissue barriers · 2025Article
- Gut microbiota - bidirectional modulator: role in inflammatory bowel disease and colorectal cancer.Frontiers in immunology · 2025Review
- Genetically engineered bacteria as inflammatory bowel disease therapeutics.Engineering microbiology · 2024Review
- The Gut Microbiome Advances Precision Medicine and Diagnostics for Inflammatory Bowel Diseases.International journal of molecular sciences · 2024Review
- Recent advances in bacteria-based platforms for inflammatory bowel diseases treatment.Exploration (Beijing, China) · 2024Review
- Deconstructing synthetic biology across scales: a conceptual approach for training synthetic biologists.Nature communications · 2024Review
- Core microbiome-associated proteins associated with ulcerative colitis interact with cytokines for synergistic or antagonistic effects on gut bacteria.The ISME journal · 2024Article
- Accelerating Genetic Sensor Development, Scale-up, and Deployment Using Synthetic Biology.Biodesign research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Inflammatory bowel disease (IBD) is a spectrum of autoimmune diseases affecting the gastrointestinal tract characterized by a relapsing and remitting course of gut mucosal inflammation. Disease flares can be difficult to predict, and the current practice of IBD disease activity surveillance through endoscopy is invasive and requires medical expertise. Recent advancements in synthetic biology raise the possibility that symbiotic microbes can be engineered to selectively detect disease biomarkers used in current clinical practice. Here, we introduce an engineered probiotic capable of detecting the clinical gold standard IBD biomarker, calprotectin, with sensitivity and specificity in IBD patients. Specifically, we identified a bacterial promoter in the probiotic strain
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.